

DAFTAR PUSTAKA

- Baloch, Z. W., Asa, S. L., Barletta, J. A., Ghossein, R. A., Juhlin, C. C., Jung, C. K., LiVolsi, V. A., Papotti, M. G., Sobrinho-Simões, M., Tallini, G., & Mete, O. (2022). Overview of the 2022 WHO Classification of Thyroid Neoplasms. In *Endocrine Pathology* (Vol. 33, Number 1, pp. 27-63). Springer. <https://doi.org/10.1007/s12022-022-09707-3>
- Benvenega, S., Tuccari, G., Ieni, A., & Vita, R. (2018). Thyroid gland: Anatomy and physiology. In *Encyclopedia of Endocrine Diseases* (pp. 382-390). Elsevier. <https://doi.org/10.1016/B978-0-12-801238-3.96022-7>
- Bychkov, A., Sampatanukul, P., Shuangshoti, S., & Keelawat, S. (2016a). TROP-2 immunohistochemistry: a highly accurate method in the differential diagnosis of papillary thyroid carcinoma. *Pathology*, 48(5), 425-433. <https://doi.org/10.1016/j.pathol.2016.04.002>
- Chapter 2. *Thyroid Hormone Synthesis and Secretion*. (n.d.).
- Chuang, H. W., Wang, J. S., Tsai, J. W., Hsu, C. T., & Lin, K. J. (2021b). Immunohistochemistry helps to distinguish noninvasive follicular thyroid neoplasm with papillary-like nuclear features/noninvasive encapsulated follicular variant of papillary thyroid carcinoma with other follicular thyroid lesions. *Medicina (Lithuania)*, 57(11). <https://doi.org/10.3390/medicina57111246>
- Dralle, H., MacHens, A., Basa, J., Fatourech, V., Franceschi, S., Hay, I. D., Nikiforov, Y. E., Pacini, F., Pasieka, J. L., & Sherman, S. I. (2015a). Follicular cell-derived thyroid cancer. *Nature Reviews Disease Primers*, 1. <https://doi.org/10.1038/nrdp.2015.77>
- Eid, A., & Abo Safia, H. (2021). TROP-2: a unique immunohistochemical marker for diagnosis of papillary thyroid carcinoma. *International Journal of Cancer and Biomedical Research*, 0(0), 0-0. <https://doi.org/10.21608/jcbr.2020.41458.1066>
- El Sewedy, T., Fornaro, M., & Alberti, S. (1998). Cloning of the murine TROP2 gene: Conservation of a PIP2-binding sequence in the cytoplasmic domain of TROP-2. *International Journal of Cancer*, 75(2), 324-330. [https://doi.org/10.1002/\(sici\)1097-0215\(19980119\)75:2<324::aid-ijc24>3.3.co;2-5](https://doi.org/10.1002/(sici)1097-0215(19980119)75:2<324::aid-ijc24>3.3.co;2-5)
- Goldenberg, D. M., Stein, R., & Sharkey, R. M. (2018). The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. In *Oncotarget* (Vol. 9, Number 48). www.oncotarget.com
- Guan, H., Guo, Z., Liang, W., Li, H., Wei, G., Xu, L., Xiao, H., & Li, Y. (2017). Trop2 enhances invasion of thyroid cancer by inducing MMP2 through ERK and JNK pathways. *BMC Cancer*, 17(1). <https://doi.org/10.1186/s12885-017-3475-2>
- Guerra, E., Trerotola, M., Aloisi, A. L., Tripaldi, R., Vacca, G., La Sorda, R., Lattanzio, R., Piantelli, M., & Alberti, S. (2013a). The Trop-2 signalling network in cancer growth. *Oncogene*, 32(12), 1594-1600. <https://doi.org/10.1038/onc.2012.151>

- Haugen, B. R., Alexander, E. K., Bible, K. C., Doherty, G. M., Mandel, S. J., Nikiforov, Y. E., Pacini, F., Randolph, G. W., Sawka, A. M., Schlumberger, M., Schuff, K. G., Sherman, S. I., Sosa, J. A., Steward, D. L., Tuttle, R. M., & Wartofsky, L. (2016). 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. *Thyroid*, 26(1), 1-133. <https://doi.org/10.1089/thy.2015.0020>
- Jung, C. K., Bychkov, A., & Kakudo, K. (2022a). Update from the 2022 World Health Organization Classification of Thyroid Tumors: A Standardized Diagnostic Approach. In *Endocrinology and Metabolism* (Vol. 37, Number 5, pp. 703-718). Korean Endocrine Society. <https://doi.org/10.3803/EnM.2022.1553>
- Katoh, H., Yamashita, K., Enomoto, T., & Watanabe, M. (2015b). Classification and General Considerations of Thyroid Cancer. *Ann Clin Pathol*, 3(1), 1045.
- Koga, N., Hu, Q., Sakai, A., Takada, K., Nakanishi, R., Hisamatsu, Y., Ando, K., Kimura, Y., Oki, E., Oda, Y., & Mori, M. (2021). Clinical significance of signal regulatory protein alpha (SIRP α) expression in esophageal squamous cell carcinoma. *Cancer Science*, 112(8), 3018-3028. <https://doi.org/10.1111/cas.14971>
- Lenárt, S., Lenárt, P., Šmarda, J., Remšík, J., Souček, K., & Beneš, P. (2020c). Trop2: Jack of all trades, master of none. In *Cancers* (Vol. 12, Number 11, pp. 1-28). MDPI AG. <https://doi.org/10.3390/cancers12113328>
- Lipinski, M., Parks, D. R., Rouse, R. V., & Herzenberg, L. A. (1981). Human trophoblast cell-surface antigens defined by monoclonal antibodies (choriocarcinoma/fetal cells/fluorescence-activated cell-sorter). In *Proc. Natl Acad. Sci. USA* (Vol. 78, Number 8). <https://www.pnas.org>
- Liu, H., Shi, J., & Lin, F. (2016). *The Potential Diagnostic Utility of TROP-2 in Thyroid Neoplasms*. www.appliedimmunohist.com
- Liu, T., Liu, Yueyang, Bao, X., Tian, J., Liu, Yang, & Yang, X. (2013b). Overexpression of TROP2 Predicts Poor Prognosis of Patients with Cervical Cancer and Promotes the Proliferation and Invasion of Cervical Cancer Cells by Regulating ERK Signaling Pathway. *PLoS ONE*, 8(9). <https://doi.org/10.1371/journal.pone.0075864>
- Liu, X., Deng, J., Yuan, Y., Chen, W., Sun, W., Wang, Y., Huang, H., Liang, B., Ming, T., Wen, J., Huang, B., & Xing, D. (2022). Advances in Trop2-targeted therapy: Novel agents and opportunities beyond breast cancer. In *Pharmacology and Therapeutics* (Vol. 239). Elsevier Inc. <https://doi.org/10.1016/j.pharmthera.2022.108296>
- Livolsi, V. A. (2011). Papillary thyroid carcinoma: An update. *Modern Pathology*, 24, S1-S9. <https://doi.org/10.1038/modpathol.2010.129>
- Lyu, Z., Zhang, Y., Sheng, C., Huang, Y., Zhang, Q., & Chen, K. (2024). Global burden of thyroid cancer in 2022: Incidence and mortality

- estimates from GLOBOCAN. *Chinese Medical Journal*, 137(21), 2567-2576. <https://doi.org/10.1097/CM9.0000000000003284>
- McHenry, C. R., & Phitayakorn, R. (2011). Follicular Adenoma and Carcinoma of the Thyroid Gland. *The Oncologist*, 16(5), 585-593. <https://doi.org/10.1634/theoncologist.2010-0405>
- Naser, A. N., Lu, Q., & Chen, Y. H. (2023). Trans-Compartmental Regulation of Tight Junction Barrier Function. In *Tissue Barriers* (Vol. 11, Number 4). Taylor and Francis Ltd. <https://doi.org/10.1080/21688370.2022.2133880>
- Nikiforova, M. N., Lynch, R. A., Biddinger, P. W., Alexander, E. K., Dorn, G. W., Tallini, G., Kroll, T. G., & Nikiforov, Y. E. (2003). RAS point mutations and PAX8-PPAR γ rearrangement in thyroid tumors: Evidence for distinct molecular pathways in thyroid follicular carcinoma. *Journal of Clinical Endocrinology and Metabolism*, 88(5), 2318-2326. <https://doi.org/10.1210/jc.2002-021907>
- Pan, J., Ye, F., Yu, C., Zhu, Q., Li, J., Zhang, Y., Tian, H., Yao, Y., Zhu, M., Shen, Y., Zhu, F., Wang, Y., Zhou, X., Guo, G., & Wu, Y. (2021a). Papillary Thyroid Carcinoma Landscape and Its Immunological Link With Hashimoto Thyroiditis at Single-Cell Resolution. *Frontiers in Cell and Developmental Biology*, 9. <https://doi.org/10.3389/fcell.2021.758339>
- Raouf, S. M. A., Atia, H., Soliman, S. A., Elshahidy, T. M., & Mohamed, S. Y. (2020). Diagnostic Utility of Immunohistochemical Markers Trop2 and CD56 in Differentiating Follicular Derived Thyroid Lesions. *La Prensa Medica Argentina*, 106(6). <https://doi.org/10.47275/0032-745x-246>
- Ripani, E., Sacchetti, A., Corda, D., & Alberti, S. (1998). HUMAN TROP-2 IS A TUMOR-ASSOCIATED CALCIUM SIGNAL TRANSDUCER. In *J. Cancer* (Vol. 76). Wiley-Liss, Inc.
- Scopa, C. D. (n.d.). *Histopathology of Thyroid Tumors. An Overview*.
- Shi, B., Chu, J., Huang, T., Wang, X., Li, Q., Gao, Q., Xia, Q., & Luo, S. (2021). The Scavenger Receptor MARCO Expressed by Tumor-Associated Macrophages Are Highly Associated With Poor Pancreatic Cancer Prognosis. *Frontiers in Oncology*, 11. <https://doi.org/10.3389/fonc.2021.771488>
- Simms, A., Jacob, R. P., Cohen, C., & Siddiqui, M. T. (2016b). TROP-2 expression in papillary thyroid carcinoma: Potential Diagnostic Utility. *Diagnostic Cytopathology*, 44(1), 26-31. <https://doi.org/10.1002/dc.23382>
- Sudarmanto, A. M., Prajoko, Y. W., Istiadi, H., & Yudhanto, E. (2024). Profile of Thyroid Cancer at Dr. Kariadi General Hospital Semarang in 2020. *Indonesian Journal of Cancer*, 18(1), 16-20. <https://doi.org/10.33371/ijoc.v18i1.1017>
- Sugimura-Nagata, A., Koshino, A., Inoue, S., Matsuo-Nagano, A., Komura, M., Riku, M., Ito, H., Inoko, A., Murakami, H., Ebi, M., Ogasawara, N., Tsuzuki, T., Takahashi, S., Kasugai, K., Kasai, K., & Inaguma, S. (2021). Article expression and prognostic significance of cd47-sirpa

- macrophage checkpoint molecules in colorectal cancer. *International Journal of Molecular Sciences*, 22(5), 1-12.
<https://doi.org/10.3390/ijms22052690>
- Tallini, G., Tuttle, R. M., & Ghossein, R. A. (2017). The history of the follicular variant of papillary thyroid carcinoma. In *Journal of Clinical Endocrinology and Metabolism* (Vol. 102, Number 1, pp. 15-22). Endocrine Society. <https://doi.org/10.1210/jc.2016-2976>
- Xia, Y., Li, B., Gao, N., Xia, H., Men, Y., Liu, Y., Liu, Z., Chen, Q., & Li, L. (2014). Expression of tumor-associated calcium signal transducer 2 in patients with salivary adenoid cystic carcinoma: Correlation with clinicopathological features and prognosis. *Oncology Letters*, 8(4), 1670-1674. <https://doi.org/10.3892/ol.2014.2400>
- Yang, X., Hu, Y., Shi, H., Zhang, C., Wang, Z., Liu, X., Chen, H., Zhang, L., & Cui, D. (2018a). The diagnostic value of TROP-2, SLP-2 and CD56 expression in papillary thyroid carcinoma. *European Archives of Oto-Rhino-Laryngology*, 275(8), 2127-2134. <https://doi.org/10.1007/s00405-018-5045-x>
- Ye, X., Zhang, J., Lu, R., & Zhou, G. (2016). *Oncotarget 1* www.impactjournals.com/oncotarget Signal regulatory protein a associated with the progression of oral leukoplakia and oral squamous cell carcinoma regulates phenotype switch of macrophages. www.impactjournals.com/oncotarget/
- Zaman, S., Jadid, H., Denson, A. C., & Gray, J. E. (2019). Targeting trop-2 in solid tumors: Future prospects. In *OncoTargets and Therapy* (Vol. 12, pp. 1781-1790). Dove Medical Press Ltd.
<https://doi.org/10.2147/OTT.S162447>
- Zargari, N., & Mokhtari, M. (2019a). Evaluation of Diagnostic Utility of Immunohistochemistry Markers of TROP-2 and HBME-1 in the Diagnosis of Thyroid Carcinoma. *European Thyroid Journal*, 8(1), 1-6.
<https://doi.org/10.1159/000494430>
- Zeng, P., Chen, M. Bin, Zhou, L. N., Tang, M., Liu, C. Y., & Lu, P. H. (2016). Impact of TROP2 expression on prognosis in solid tumors: A Systematic Review and Meta-analysis. In *Scientific Reports* (Vol. 6). Nature Publishing Group. <https://doi.org/10.1038/srep33658>

Lampiran



KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.



Contact Person: dr. Aguslilim Bukhari, MMed, PhD, SpCK TELP. 081241850858, 0411 5780103, Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK

Nomor : 1013/UN4.6.4.5.31/ PP36/ 2025

Tanggal: 25 Nopember 2025

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH25090762	No Sponsor	
Peneliti Utama	dr. Citra Abadi Anshar	Sponsor	
Judul Peneliti	EKSPRESI TROP2 PADA ADENOMA FOLIKULER TIROID, KARSINOMA FOLIKULER TIROID, KARSINOMA PAPILER TIROID VARIAN FOLIKULER DAN KARSINOMA PAPILER TIROID		
No Versi Protokol	1	Tanggal Versi	25 September 2025
No Versi PSP		Tanggal Versi	
Tempat Penelitian	RS Universitas Hasanuddin Makassar		
Jenis Review	☐ Exempted ☒ Expedited ☐ Fullboard Tanggal	Masa Berlaku 25 Nopember 2025 sampai 25 Nopember 2026	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Prof. dr. Muh Nasrum Massi, PhD, SpMK, Subsp. Bakt(K)	Tanda tangan	
Sekretaris KEP Universitas Hasanuddin	Prof. dr. Firdaus Hamid, PhD, SpMK(K)	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan